The estimated Net Worth of Venture Partners V Lp Skyli... is at least 67.6 百万$ dollars as of 19 October 2018. Venture Skyli owns over 325,000 units of SI-BONE Inc stock worth over 66,653,374$ and over the last 11 years Venture sold SIBN stock worth over 976,583$.
Venture has made over 3 trades of the SI-BONE Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture bought 325,000 units of SIBN stock worth 4,875,000$ on 19 October 2018.
The largest trade Venture's ever made was buying 325,000 units of SI-BONE Inc stock on 19 October 2018 worth over 4,875,000$. On average, Venture trades about 187,511 units every 573 days since 2014. As of 19 October 2018 Venture still owns at least 4,419,985 units of SI-BONE Inc stock.
You can see the complete history of Venture Skyli stock trades at the bottom of the page.
Over the last 6 years, insiders at SI-BONE Inc have traded over 114,943,926$ worth of SI-BONE Inc stock and bought 1,250,000 units worth 18,750,000$ . The most active insiders traders include David P Bonita、Advisors Llc Orbi Med Capit...、John Gordon Freund. On average, SI-BONE Inc executives and independent directors trade stock every 8 days with the average trade being worth of 401,535$. The most recent stock trade was executed by Anshul Maheshwari on 3 September 2024, trading 1,414 units of SIBN stock currently worth 23,119$.
si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al
SI-BONE Inc executives and other stock owners filed with the SEC include: